Mohammed M. Alanazi

New quinoxaline derivatives as VEGFR-2 inhibitors with anticancer and apoptotic activity: Design, molecular modeling, and synthesis

Nawaf A. Alsaif, Mohammed A. Dahab, Mohammed M. Alanazi et al. · Bioorganic Chemistry · 2021 · 105 citations

Pharmacy, Medicinal Chemistry, Pharmacology +17

New bis([1,2,4]triazolo)[4,3-a:3′,4′-c]quinoxaline derivatives as VEGFR-2 inhibitors and apoptosis inducers: Design, synthesis, in silico studies, and anticancer evaluation

Mohammed M. Alanazi, Hazem A. Mahdy, Nawaf A. Alsaif et al. · Bioorganic Chemistry · 2021 · 96 citations

Pharmacy, Medicinal Chemistry, Pharmacology +15

Novel thiophene Chalcones-Coumarin as acetylcholinesterase inhibitors: Design, synthesis, biological evaluation, molecular docking, ADMET prediction and molecular dynamics simulation

Aso Hameed Hasan, Sankaranarayanan Murugesan, Syazwani Itri Amran et al. · Bioorganic Chemistry · 2021 · 95 citations

Pharmacy, Medicinal Chemistry, Pharmacology +17

Design, synthesis, docking, ADMET studies, and anticancer evaluation of new 3-methylquinoxaline derivatives as VEGFR-2 inhibitors and apoptosis inducers

Mohammed M. Alanazi, Ibrahim H. Eissa, Nawaf A. Alsaif et al. · Journal of Enzyme Inhibition and Medicinal Chemistry · 2021 · 92 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +13

New quinoxaline-based VEGFR-2 inhibitors: design, synthesis, and antiproliferative evaluation with <i>in silico</i> docking, ADMET, toxicity, and DFT studies

Mohammed M. Alanazi, Hazem Elkady, Nawaf A. Alsaif et al. · RSC Advances · 2021 · 68 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +13